Drug updated on 5/17/2024
Dosage Form | Tablet (oral; 120 mg) |
Drug Class | RAS GTPase family inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Sotorasib (Lumakras) is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, who have received at least one prior systemic therapy.
- A single systematic review/meta-analysis focused on the efficacy and safety of KRAS^G12C inhibitors, specifically sotorasib and adagrasib, in treating solid tumors.
- The meta-analysis involved 18 studies with a total of 1,224 patients having KRAS^G12C-mutated solid tumors.
- Results from this analysis showed an objective response rate (ORR) of 31%, disease control rate (DCR) of 86%, and incidence rate of grade ≥3 adverse events (AEs) at 29% among these patients treated with sotorasib.
- Patients harboring a co-mutation in KEAP1 had worse ORRs compared to those without it when treated with sotorasib, indicating that genetic profiling could be crucial in identifying patient subgroups likely to benefit most from such targeted treatments.
- While direct comparison data between Lumakras (sotorasib), adagrasib, and other treatments were not provided within this study; based on available information, Lumakras provides meaningful clinical benefits along with manageable side effects for patients suffering from NSCLC carrying the specific mutation.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Lumakras (sotorasib) Prescribing Information. | 2023 | Amgen Inc., Thousand Oaks, CA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: a systematic review and meta-analysis. | 2024 | Pharmacological Research |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. | 2023 | Current Oncology |